Adverse Drug Reaction

Group opposes over-the-counter status for Mevacor

Published in OBGYN and Reproduction Week, February 14th, 2005

The March of Dimes opposes over-the-counter (OTC) status for Mevacor (lovastatin), a Pregnancy Category X drug (i.e., one that should not be taken during pregnancy).

The March of Dimes comments came at a joint meeting in January 2005 of the U.S. Food and Drug Administration's Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees.

The March of Dimes says some published data suggest that lovastatin may be teratogenic (capable of causing birth defects with fetal exposure). Changing lovastatin to OTC would reduce the ability of pregnant women to receive appropriate medical counseling on the potential risks of fetal exposure to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week

Source: OBGYN and Reproduction Week (2005-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry